Cancer is one of the most dynamic areas of research in clinical laboratory medicine. The ability to perform molecular and genetic testing have opened up a world of possibilities for new screening and detection technologies, and the first webinar in this series looks at a promising new technology for detecting circulating tumor cells in the blood.
As technology advances, more traditional (but less sensitive and specific) tests are being replaced by a newer generation of more accurate assays that are changing clinical practice. Fecal immunochemical tests for hemoglobin that are now being used to screen patients for colorectal cancer are one example, and they will be discussed in the second webinar of this series.
In the third webinar, a world-renowned prostate cancer expert examines what the future hold in store for prostate cancer detection, examining the potential of multi-analyte panels for detecting this highly prevalent disease.
Viable Circulating Tumor Cells from Patient Blood: A Chip-free Approach for Clinical Labs
Michael King, PhD, Associate Professor of Biomedical Engineering, Cornell University Center on the Microenvironment and Metastasis, Ithaca, NY
New Developments in Colorectal Cancer Screening
Callum G. Fraser, PhD, Senior Advisor to the Scottish Bowel Screening Programme, Honorary Professor at the University of Dundee, and Honorary Consultant Clinical Biochemist to the National Health Service, Tayside, Scotland
Advances in Prostate Cancer Detection: What’s Next for Clinical Labs?
William Catalona, MD, Professor of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL